Esperite N.V. convenes EGM to change auditor
(Thomson Reuters ONE) -
Esperite N.V. (Euronext: ESP, 'Esperite', or 'the Group'), the European leader
in stem cells cryopreservation, now entering the fields of predictive medicine
and translational regenerative medicine R&D, announces it is convening an extra-
ordinary general meeting of shareholders ("EGM") to be held on Thursday 18
December 2014 to change its auditor.
On 14 May 2014 the shareholders meeting appointed KPMG Accountants N.V. as
external auditor for a term of 1 year. Since the 14 May 2014 appointment,
however, the Company has not been able to agree appropriate fees for the 2014
audit with KPMG. The fees proposed by KPMG represent a substantial increase in
comparison with its previous audits of the Company's annual financial
statements, with the Company disagreeing with the argumentation that KPMG
provided as justification for this increase. Furthermore, KPMG's fee proposal
was much higher than other reputable audit firms have proposed to the Company
during a tender audit process it has conducted.
Also given the Company's cost cutting exercise and stringent cash management,
the Board of Directors is of the opinion that maintaining KPMG as the external
auditor in relation to the 2014 audit is no longer justified or appropriate.
Consequently, the Board of Directors proposes that the EGM withdraws the 14 May
2014 appointment of KPMG Accountants N.V. as the Company's external auditor, and
instead appoints EY Accountants LLP as external auditor for a term of 1 year.
Appointing EY Accountants LLP as the Company's external auditor for the 2014
audit will result in substantially lower 2014 audit costs than such costs would
have amounted to if KPMG were to conduct the 2014 audit on the basis of its fee
proposal.
The EGM's convocation notice, agenda and the explanatory notes to the agenda are
available free of charge at the Company's offices in Zutphen, the Netherlands
and can be downloaded from the Company's website, www.esperite.com.
Enquiries: Esperite + 31 (0) 575 548 998
Frédéric Amar, Chief Executive Officer
About Esperite (www.esperite.com)
Esperite, the leading international company in regenerative and predictive
medicine. Its family stem cell bank, CryoSave, stores almost 275,000 samples
from umbilical cord blood and cord tissue. There are already many diseases
treatable by the use of stem cells, and the number of treatments will only
increase. Esperite has cryopreserved samples from over 70 countries on six
continents, with ultra-modern processing and storage facilities in Belgium,
Switzerland, Germany, Dubai, South Africa and Portugal.
PDF: Press Release EGM:
http://hugin.info/143308/R/1869579/657383.PDF
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Esperite N.V. via GlobeNewswire
[HUG#1869579]
Unternehmensinformation / Kurzprofil:
Datum: 06.11.2014 - 19:09 Uhr
Sprache: Deutsch
News-ID 350510
Anzahl Zeichen: 3533
contact information:
Town:
Zutphen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Esperite N.V. convenes EGM to change auditor"
steht unter der journalistisch-redaktionellen Verantwortung von
Esperite N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
